MSH began working in Indonesia in 1980 with the Health Training Research and Development Project and is currently implementing programming through the Tuberculosis Care I Program (TB Care I), building upon MSH’s success in the Tuberculosis Control Assistance Program (TB CAP). Furthermore, MSH has also recently implemented child health work through Basic Support for Institutionalizing Child Survival Project (BASICS), built capacity of the local health system through the Grants Management Solutions Project (GMS), and supported the pharmaceutical system through Strengthening Pharmaceutical System (SPS) Project. Other historic MSH programs in in pharmaceutical management, health systems strengthening, and health service delivery include the Special Assistance for Project Formulation Project, the Drug Management Program, the International Network for Rational Use of Drugs Initiative, the Management and Leadership Program, and the Health Sector Financing Project: Technical Assistance on Pharmaceutical Management.
In terms of TB, there is declining trend of prevalence and incidence, with 302,861 all TB cases and 296,272 new TB cases reported in 2010. These numbers bring Indonesia to country with fourth highest tuberculosis burden. Case notification rate in Indonesia is 74.4 per 100,000 populations in 2010. Treatment success rate is 91%. MDR remains a problem in Indonesia with a rate of 1.8%. A hundred and forty two MDR-TB patients are put into treatment in 2010. There are 25% TB patients with known HIV status among all registered TB patients. While the percentage of HIV patients with known TB status is 92%.
TB CARE I in Indonesia was started in 2010 and is led by KNCV Tuberculosis Foundation with 6 collaborative partners (ATS, FHI, JATA, MSH, The Union, WHO). TB CARE support is primarily in district and provincial level, but also provides assistance in national level. TB CARE I area comprises 11 provinces and works in 8 technical areas. Priorities in following year are:
- Universal access: Ensure universal access to quality TB services through expansion of HDL, TB control in prison, and TB service delivery support for people living in remote areas
- Laboratory: Strengthen the laboratory network and quality assurance for laboratories including implementation of GeneXpert MTB/RIF
- TB Infection Control: Increase political commitment in TB IC and scale up the implementation
- PMDT: Improve the quality of PMDT in existing sites and scale up PMDT to new sites
- TB/HIV: Strengthen TB/HIV collaborative mechanism in all levels and decrease TB burden in HIV patients and HIV burden in TB patients
- Health System Strengthening: Ensure TB as priority in national health plans and strategies
- M&E, Surveillance and Operational Research: Improve TB surveillance especially case-based reporting from district to national level, improve functioning of e-TB manager and scale up e-TB Manager to new sites in accordance with the PMDT expansion plan and improve capacity for operational research
- Drug Management: Improve drug and pharmaceutical management to ensure uninterrupted supply of first and second line TB drugs to all health facilities